艾欧凡斯生物治疗

US · IOVA #1864 按市值排名上市于 1970

13.62 -1.10 -7.47%

实时 - 追踪5344个代码 - 心跳于270秒前 · 2026-10-16 19:58

✦ 量化股权信号计算方式说明

增持

最近一期（2026/Q3）披露持股的机构数量减少了1家。
机构持股总比例上升了0.4个百分点。

机构持股

机构持股比例: 64.18% +0.37pp
机构数量: 332 -1
数据截至: 2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund37.62%

Hedge Fund12.23%

Individual/Insider6.56%

VC/PE Fund6.39%

Public Company4.18%

Private Company2.79%

Insurance Company0.63%

Government Pension Fund0.30%

Other29.27%

主要股东截至 2026-06-30

BlackRock 8.16% · 36.96M 股

MHR Fund Management LLC 6.39% · 28.97M 股

Wayne Rothbaum 6.20% · 28.07M 股

State Street Global Advisors 5.40% · 24.48M 股

Vanguard Capital Management, LLC 4.58% · 20.75M 股

Two Sigma Investments, LP 4.20% · 19.01M 股

Vanguard Portfolio Management, LLC 3.18% · 14.39M 股

Geode Capital Management, LLC 2.28% · 10.32M 股

Millennium Management LLC 1.88% · 8.53M 股

Dimensional Fund Advisors 1.43% · 6.46M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 32次买入 · 18次卖出

姓名	职务	持股比例
Wayne Rothbaum	Independent Director	6.20%
Frederick Vogt	Interim CEO, President, General Counsel & Corporate Secretary	0.13%
Raj Puri	Executive VP of Regulatory Strategy & Translational Medicine	0.06%
Daniel Kirby	Chief Commercial Officer	0.03%
Igor Bilinsky	Chief Operating Officer	0.03%
Michael Weiser	Independent Director	0.03%
Friedrich Graf Finckenstein	Chief Medical Officer	0.03%
Matthew Rosinack	Interim Principal Financial Officer & Principal Accounting Officer	0.02%
Iain Dukes	Independent Chairperson	0.01%
Corleen Roche	Chief Financial Officer	0.01%

内部人交易最近的 Form 4 申报记录

日期	姓名	职务	类型	股数	价格
2026-09-29	Noah Berkowitz	Chief Medical Officer	Other Derivative Acquisition	+135,000	$14.82
2026-09-29	Noah Berkowitz	Chief Medical Officer	Other Derivative Acquisition	+180,000	--
2026-09-07	Igor Bilinsky	Chief Operating Officer	Derivative Exercise and Sale	-3,976	$8.70
2026-09-07	Igor Bilinsky	Chief Operating Officer	Derivative Exercise and Retained	+3,837	--
2026-09-07	Frederick Vogt	Interim CEO, President, General Counsel & Corporate Secretary	Derivative Exercise and Sale	-6,638	$8.70
2026-09-07	Frederick Vogt	Interim CEO, President, General Counsel & Corporate Secretary	Derivative Exercise and Retained	+8,988	--
2026-09-07	Raj Puri	Executive VP of Regulatory Strategy & Translational Medicine	Derivative Exercise and Sale	-4,478	$8.70
2026-09-07	Raj Puri	Executive VP of Regulatory Strategy & Translational Medicine	Derivative Exercise and Retained	+5,288	--
2026-08-31	Igor Bilinsky	Chief Operating Officer	Derivative Exercise and Sale	-4,472	$8.28
2026-08-31	Igor Bilinsky	Chief Operating Officer	Derivative Exercise and Retained	+4,317	--
2026-08-31	Frederick Vogt	Interim CEO, President, General Counsel & Corporate Secretary	Derivative Exercise and Sale	-17,702	$8.28
2026-08-31	Frederick Vogt	Interim CEO, President, General Counsel & Corporate Secretary	Derivative Exercise and Retained	+23,967	--
2026-08-31	Raj Puri	Executive VP of Regulatory Strategy & Translational Medicine	Derivative Exercise and Sale	-2,508	$8.28
2026-08-31	Raj Puri	Executive VP of Regulatory Strategy & Translational Medicine	Derivative Exercise and Retained	+2,962	--
2026-08-09	Daniel Kirby	Chief Commercial Officer	Derivative Exercise and Sale	-2,436	$6.40
2026-08-09	Daniel Kirby	Chief Commercial Officer	Derivative Exercise and Retained	+7,565	--
2026-08-05	Corleen Roche	Chief Financial Officer	Derivative Exercise and Sale	-21,238	$6.21
2026-08-05	Corleen Roche	Chief Financial Officer	Derivative Exercise and Retained	+28,757	--
2026-06-15	Michael Weiser	Independent Director	Other Derivative Acquisition	+90,316	--
2026-06-15	Ryan Maynard	Independent Director	Other Derivative Acquisition	+90,316	--

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:58:42 · 仅供参考，不构成投资建议，也未考虑您的具体情况。